Psyence Biomedical Ltd. ( PBM ) , a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an update to shareholders, highlighting significant recent developments and upcoming milestones. The company has initiated a Phase IIb clinical trial in Australia to evaluate psilocybin-assisted therapy for Adjustment Disorder in palliative care. Results are expected in late...

Over the weekend, Nuvalent, Inc ( NUVL ). highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 trial of NVL-655, at the European Society for Medical Oncology (ESMO) Congress 2024. In total, 227 patients were enrolled in the Phase 2 portion of the ARROS-1 trial of zidesamtinib...

01:41 PM EDT, 09/16/2024 (MT Newswires) -- Price: 184.50, Change: -1.99, Percent Change: -1.07 ...

Exicure, Inc. ( XCUR ) stock is trading higher on Monday after the company entered into debt-for-equity exchange agreements. What Happened: On Friday, Exicure ( XCUR ) filed a Form 8-K with the Securities and Exchange Commission that signaled that it entered into debt-for-equity agreements with DGP and another with a separate individual. DGP, Exicure’s largest shareholder, holds about 35%...